ATE547411T1 - 3-pyrrolo-cyclohexylen-2-dihydroindolinonderiva e und anwendungen davon - Google Patents

3-pyrrolo-cyclohexylen-2-dihydroindolinonderiva e und anwendungen davon

Info

Publication number
ATE547411T1
ATE547411T1 AT07817351T AT07817351T ATE547411T1 AT E547411 T1 ATE547411 T1 AT E547411T1 AT 07817351 T AT07817351 T AT 07817351T AT 07817351 T AT07817351 T AT 07817351T AT E547411 T1 ATE547411 T1 AT E547411T1
Authority
AT
Austria
Prior art keywords
cyclohexylene
pyrrolo
activity
formula
pharmaceutically acceptable
Prior art date
Application number
AT07817351T
Other languages
English (en)
Inventor
Feng Tang
Han Shen
Qiu Jin
Lei Ding
Jie Yang
Xiaojin Yin
Shiyue Lu
Original Assignee
Jiangsu Simcere Pharmaceutical R & D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNA200610098202XA external-priority patent/CN101195601A/zh
Priority claimed from CNA2006101612208A external-priority patent/CN101200446A/zh
Application filed by Jiangsu Simcere Pharmaceutical R & D Co Ltd filed Critical Jiangsu Simcere Pharmaceutical R & D Co Ltd
Application granted granted Critical
Publication of ATE547411T1 publication Critical patent/ATE547411T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT07817351T 2006-12-04 2007-12-03 3-pyrrolo-cyclohexylen-2-dihydroindolinonderiva e und anwendungen davon ATE547411T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNA200610098202XA CN101195601A (zh) 2006-12-04 2006-12-04 2-二氢吲哚酮衍生物及其制备方法和用途
CNA2006101612208A CN101200446A (zh) 2006-12-15 2006-12-15 3-吡咯并环己亚基-2-二氢吲哚酮衍生物及其用途
PCT/CN2007/071161 WO2008067756A1 (fr) 2006-12-04 2007-12-03 Dérivés de 3-pyrrolo-cyclohexylène-2-dihydro-indolinone et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
ATE547411T1 true ATE547411T1 (de) 2012-03-15

Family

ID=39491676

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07817351T ATE547411T1 (de) 2006-12-04 2007-12-03 3-pyrrolo-cyclohexylen-2-dihydroindolinonderiva e und anwendungen davon

Country Status (6)

Country Link
US (1) US8084621B2 (de)
EP (1) EP2123649B1 (de)
JP (1) JP5542445B2 (de)
AT (1) ATE547411T1 (de)
ES (1) ES2383084T3 (de)
WO (1) WO2008067756A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2816559C (en) 2010-11-01 2018-02-13 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Processes for the preparation of 3-((pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
EP2668190B1 (de) 2011-01-26 2016-08-17 Nerviano Medical Sciences S.r.l. Tricyclische pyrroloderivate, verfahren zu ihrer herstellung und ihre verwendung als kinasehemmer
CN102675184A (zh) * 2011-03-15 2012-09-19 江苏先声药物研究有限公司 一种酪氨酸激酶抑制剂的盐形式
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103664738B (zh) * 2012-09-12 2016-07-13 南京优科生物医药研究有限公司 一种羧酰胺化合物l-苹果酸盐的结晶多晶型物
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505597A (ja) 2012-12-21 2016-02-25 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
CA2899363A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN118974016A (zh) * 2022-04-01 2024-11-15 康百达（四川）生物医药科技有限公司 吲哚酮衍生物及其在医药上的应用
WO2024188282A1 (zh) * 2023-03-14 2024-09-19 康百达（四川）生物医药科技有限公司 吲哚酮衍生物及其在医药上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316429B1 (en) * 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
JP2002523455A (ja) * 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体
FR2801216A1 (fr) 1999-11-23 2001-05-25 Centre Nat Rech Scient Utilisation de derives d'indirubine pour la fabrication de medicaments
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
DE10125763A1 (de) 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
WO2005016875A2 (en) * 2003-08-06 2005-02-24 Sugen, Inc. Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
MXPA06006049A (es) 2003-11-26 2007-05-24 Scripps Research Inst Inhibidores de proteina quinasa avanzados a base de indolinona.
EP2118102B1 (de) * 2006-11-28 2013-06-12 Nerviano Medical Sciences S.r.l. Tricyclische indole und (4,5-dihydro)indole

Also Published As

Publication number Publication date
JP2010511638A (ja) 2010-04-15
EP2123649A1 (de) 2009-11-25
WO2008067756A1 (fr) 2008-06-12
EP2123649A4 (de) 2010-10-13
US8084621B2 (en) 2011-12-27
ES2383084T3 (es) 2012-06-18
US20100160318A1 (en) 2010-06-24
EP2123649B1 (de) 2012-02-29
JP5542445B2 (ja) 2014-07-09

Similar Documents

Publication Publication Date Title
ATE547411T1 (de) 3-pyrrolo-cyclohexylen-2-dihydroindolinonderiva e und anwendungen davon
CY2021019I2 (el) Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
ATE479687T1 (de) Kinaseinhibitoren
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
NO20090580L (no) Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
UA98629C2 (ru) Соединения и способ модуляции киназ
MX2009012595A (es) Derivados de espiroindolinona.
DOP2009000141A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
ECSP088121A (es) Derivados de pirrolo [2,3-b] piridina comoinhibidores de proteina cinasa
MXPA05008878A (es) Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
MX2009006688A (es) Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
EA200801680A1 (ru) Производные пиримидина, применимые в качестве ингибиторов pi-3 киназы, и способы их применения
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
ATE522509T1 (de) Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase
ATE512151T1 (de) Pyrrolotriazin-kinaseinhibitoren
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.